Download Files:
AZ084
$166 – $2,250
Products Details
Product Description
– AZ084 is a potent, selective, allosteric and oral active CCR8 allosteric antagonist, with a Ki of 0.9 nM. Has potential to treat asthma[1]. AZ084 restrains the formation of the immunologically tolerant pre-metastatic niche (PMN) and tumor cells metastasis in lung by downregulating Treg differentiation. AZ084 can be used in studies of asthma and cancer[1][2].
Web ID
– HY-119217
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C26H34N4O2
References
– [1]Wang M, et al. Tumor-derived exosomes drive pre-metastatic niche formation in lung via modulating CCL1+ fibroblast and CCR8+ Treg cell interactions. Cancer Immunol Immunother. 2022 Apr 15. |[2]Connolly S, et al. Orally bioavailable allosteric CCR8 antagonists inhibit dendritic cell, T cell and eosinophil migration. Biochem Pharmacol. 2012 Mar 15;83(6):778-87.
CAS Number
– 929300-19-6
Molecular Weight
– 434.57
Compound Purity
– 99.69
SMILES
– O=C(C1=NC=C(N)C=C1)N2CCC3(CCN(CC4=C5CC(C)(C)OC5=CC=C4)CC3)CC2
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Endocrinology
Solubility
– DMSO : 250 mg/mL (ultrasonic)
Target
– CCR
Isoform
– CCR8
Pathway
– GPCR/G Protein;Immunology/Inflammation
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
